

Equity Research Report: NovoCure Limited (NVCR) - Strategic Transition, Oncology Platform, and 2026 Catalysts

Report Date: January 18, 2026

Analyst: Dr. Alessandro Rivoli, Senior Biotech & MedTech Equity Research Analyst

Subject: Deep Dive Analysis on NovoCure (NVCR), Clinical Pipeline, Commercial Dynamics, and 2026 Catalyst Roadmap


1. Executive Summary: A Strategic Inflection Point

At the dawn of 2026, NovoCure Limited (NASDAQ: NVCR) is traversing the most critical and transformative phase in its twenty-year history. For over a decade, the market has perceived the company primarily as a "single-product" player, whose value depended almost exclusively on the success of the Optune device in treating Glioblastoma (GBM). Today, a deep analysis of fundamentals, recent clinical data, and regulatory dynamics suggests that NovoCure is in the midst of a structural metamorphosis into a true multi-product oncology "Platform Company." This transition, however, is not without operational friction and market skepticism, elements that have generated notable volatility in the share price over the last 24 months.¹

The investment thesis for 2026 is founded on an unprecedented convergence of clinical and regulatory events. The year 2025 provided the necessary clinical validation for this expansion, with the success of the Phase 3 **PANOVA-3** study in locally advanced pancreatic cancer and the **METIS** study in brain metastases from non-small cell lung cancer (NSCLC).³ These clinical successes, combined with regulatory approval in Japan for **Optune Lua** in NSCLC and the expansion of reimbursement in Europe, have laid the foundations for revenue diversification that will begin to materialize concretely during the current year.⁵

Despite clinical progress, the market maintains a cautious stance, partly justified by the initial commercial performance in the NSCLC segment, which proved slower than the most optimistic sell-side projections. Challenges related to reimbursement, particularly in Germany and the United States, and the need to integrate a device-based therapy into a treatment landscape dominated by systemic drugs, have created near-term headwinds.⁷ However, the appointment of Frank Leonard as CEO and the repayment of convertible debt in November 2025 have eliminated significant balance sheet risks, leaving the company with a solid cash position to face the anticipated multiple launches.³

Roadmap dei Catalizzatori 2026: Eventi Clinici e Normativi



Cronologia prevista dei principali eventi catalizzatori per il 2026. Le pietre miliari includono i dati top-line dello studio TRIDENT e le decisioni FDA per PANOVA-3 e METIS.

Data sources: [Stockhouse](#), [FirstWord Pharma](#), [OncoLive](#)

This report disaggregates every aspect of the pipeline and financial structure in detail, providing a holistic assessment of NovoCure's risk-reward profile as it prepares to navigate what could be the most consequential year since its IPO.

2. Scientific Foundations: The Physics of Tumor Treating Fields (TTFields)

To fully grasp NovoCure's sustainable competitive advantage (or "moat"), it is indispensable to analyze the proprietary technology underlying all its products. TTFields do not simply represent a new drug or an incremental improvement of an existing device; they constitute a "fourth modality" of cancer treatment, distinct from surgery, radiotherapy, and pharmacotherapy (chemotherapy/immunotherapy).

2.1 Primary Mechanisms of Action: Antimitotic and Dielectrophoresis

TTFields are alternating electric fields at intermediate frequencies (specifically tuned between 100 kHz and 500 kHz depending on the tumor type) and low intensity (1-3 V/cm). At these specific frequencies, the fields do not excite nerve or muscle tissues, thus avoiding side

effects such as pain or seizures, and do not generate sufficient heat to cause thermal damage to healthy tissues. Instead, the action is exquisitely targeted at the physical properties of rapidly dividing cells.¹⁰

The mechanism of action (MoA) relies on physical interaction with polar intracellular proteins, particularly tubulin and septin, which are fundamental for cell division (mitosis). These proteins possess a high electric dipole moment.

In the presence of a uniform alternating electric field:

1. **Mitotic Arrest:** During metaphase, tubulin dimers must polymerize to form the microtubules of the mitotic spindle. The external electric field exerts a torque on these dipoles, forcing them to align with the field lines. This forced alignment interferes with correct polymerization, leading to the formation of dysfunctional mitotic spindles. The cell detects this damage through cell cycle checkpoints, often leading to mitotic arrest and consequent programmed cell death (apoptosis) or "mitotic catastrophe."¹¹
2. **Dielectrophoresis:** During the final phase of division (cytokinesis), the cell assumes an hourglass shape. This geometry creates a non-uniform electric field within the cell, with maximum intensity in the narrow "neck" of the hourglass (cleavage furrow). Due to the phenomenon of dielectrophoresis, polar particles and organelles are pushed toward the region of maximum field intensity. The disordered accumulation of material in the cleavage furrow prevents the physical separation of the two daughter cells and can cause violent rupture of the cell membrane (blebbing), destroying the cell.¹³

2.2 Secondary Biological Effects and Therapeutic Synergies

Research conducted in recent years, and presented at prestigious venues like EANO 2025, has revealed that the impact of TFields goes beyond simple mechanical interruption of cell division. These "downstream effects" are crucial for explaining the clinical synergy observed when TFields are combined with other therapies.¹⁴


- **Induction of Immunogenic Cell Death (ICD):** Treatment with TFields induces significant stress in the endoplasmic reticulum of tumor cells. This stress leads to the exposure of signal molecules on the cell surface (such as calreticulin) and the release of danger signals (such as ATP and HMGB1). These signals act as a beacon for the immune system, recruiting dendritic cells and T lymphocytes into the tumor microenvironment. This mechanism provides the rationale for combination with immune checkpoint inhibitors (such as PD-1/PD-L1), as explored in the LUNAR study and the future LUNAR-2, transforming a "cold" tumor into a "hot" one from an immunological perspective.¹¹
- **Downregulation of DNA Repair:** Recent studies have demonstrated that exposure to TFields leads to a downregulation of genes involved in DNA damage repair, particularly in the Homologous Recombination (HR) pathway. Tumor cells treated with TFields thus become "BRCAness-like," or hypersensitive to agents that damage DNA, such as radiotherapy and alkylating chemotherapy (e.g., Temozolomide). This discovery is the scientific pillar of the Phase 3 **TRIDENT** study, which aims to leverage this

radiosensitization by treating patients *during* radiotherapy, not just after.¹¹

- **Increased Permeability:** There is preclinical evidence that TTFIELDS transiently increase the permeability of the cell membrane and tight junctions, potentially facilitating the entry of chemotherapeutic agents into tumor cells or across difficult biological barriers.

This versatility and the ability to tune the frequency (200 kHz for Glioma, 150 kHz for Lung and Pancreas, and other frequencies for Ovarian and Liver cancer) make the platform scalable across different tumor histologies, reducing the binary risk typical of single-target biotech companies.¹⁰

Meccanismo d'Azione Multifattoriale dei TTFIELDS



Rappresentazione schematica dell'impatto dei TTFIELDS sulle cellule tumorali in divisione. (A) Interruzione dell'assemblaggio dei microtubuli. (B) Induzione della morte cellulare immunogenica e risposta immunitaria antitumorale.

3. Financial Analysis and Corporate Health: Q3 2025 and Preliminary FY 2025

Analysis of NovoCure's financial position reveals a company that is managing the transition to the multi-product growth phase with discipline. The most recent data indicate a stabilization

of the core business and prudent cash management.

3.1 Revenue Performance and Organic Growth

According to preliminary unaudited results released on January 12, 2026, NovoCure ended the fiscal year 2025 with total net revenues of \$655.4 million, recording growth of 8% compared to the previous year.⁶

Analyzing quarterly granularity, the fourth quarter of 2025 generated revenues of \$174.4 million, also up 8% year-over-year. The geographic breakdown highlights the resilience of the U.S. market and the growth of international markets:

- **United States:** \$101.6 million in Q4, confirming its role as the primary market.
- **EMEA (Europe):** Germany contributed \$21.6 million and France \$20.5 million. The French performance is particularly noteworthy (+27% active patients in Q3), driven by national reimbursement.⁷
- **Japan:** \$10.2 million in Q4, an expanding market thanks also to the recent approval in NSCLC.⁹
- **Greater China:** Revenues from the partnership with Zai Lab were \$4.6 million in Q4, reflecting royalties on sales in the territory.⁹

A key indicator of future health is the number of active patients, which reached a record **4,620** as of December 31, 2025, an increase of 12% compared to 4,126 at the end of 2024.⁶ This positive decoupling between patient growth (+12%) and revenue growth (+8%) suggests potential for future revenue acceleration as new patients mature in the treatment cycle and reimbursement issues for new indications are resolved.

3.2 Profitability Analysis: Margin Pressure and Path to Break-Even

An element of concern for analysts during 2025 was gross margin compression. In the third quarter of 2025, gross margin fell to 73%, compared to 77% in the same period of the previous year.¹⁷

This contraction is not a symptom of structural inefficiency, but the result of three specific transitory factors:

1. **Product Launch and Mix:** The global rollout of new, thinner, and more flexible treatment arrays involved higher initial production costs that will normalize with economies of scale.
2. **Pre-Reimbursement Dynamic (NSCLC):** In key markets like Germany and the US, NovoCure began treating NSCLC patients immediately after regulatory approval, often *before* finalizing reimbursement agreements with payers. This means the company bears the full cost of goods sold (COGS) for these patients without immediately recognizing corresponding revenue, artificially depressing the margin.⁷
3. **Tariffs:** Increased global tariffs had a marginal impact on supply chain costs.

Adjusted EBITDA remains in negative territory (\$-3.0 million in Q3 2025), but the loss is narrowing. Management confirmed a crucial strategic guidance: reaching adjusted EBITDA break-even is expected when annual revenue hits the **\$700-\$750 million** threshold.

Considering the current Q4 run-rate ($\$174\text{M} \times 4 = \sim\700M), the company is extremely close to this milestone, which could be operationally reached between late 2026 and early 2027.¹⁹


3.3 Balance Sheet and Debt Management: Eliminating Convertible Risk

One of the major "overhangs" on NVCR stock over the last two years was concern regarding the ability to repay maturing convertible debt.

In November 2025, NovoCure successfully executed the repayment of \$561 million in convertible notes at maturity, using exclusively available cash on the balance sheet.⁹

- **Residual Cash Position:** As of December 31, 2025, post-repayment, the company reports **\$448.3 million** in cash and short-term investments.⁹
- **Solvency Analysis:** Although cash has decreased drastically from the peak of over \$1 billion, the residual sum of nearly \$450 million is considered adequate to fund current operations and planned commercial launches. With operational cash burn shrinking toward breakeven, the company has warded off the specter of forced equity dilution or refinancing at onerous rates in the short term. This has "cleaned up" the capital structure, making the stock more attractive to fundamental institutional investors.

Analisi Finanziaria: Crescita Ricavi vs. Pazienti Attivi (2024-2025)



Trend dei ricavi trimestrali e dei pazienti attivi. Si noti l'accelerazione dei pazienti attivi nel Q4 2025 (4.620) e la tenuta dei ricavi nonostante le pressioni sui margini.

Data sources: [Fintool](#), [BusinessWire](#), [BioSpace](#)

4. The Pancreatic Cancer Franchise: The Next Big Opportunity

2025 marked a historic turning point for NovoCure in the treatment of pancreatic ductal adenocarcinoma (PDAC), unanimously recognized as one of the most urgent unmet medical needs in oncology, with 5-year survival rates still in single digits.

4.1 Deep Analysis of the PANOVA-3 Study

The Phase 3 **PANOVA-3** study represented a bold bet: evaluating the efficacy of TTFields (150 kHz) in combination with standard chemotherapy (gemcitabine and nab-paclitaxel) as first-line treatment for patients with locally advanced, unresectable PDAC. This setting is

known to be a "graveyard" for clinical trials, with historical high-profile failures like the LAP-07 study.

The announced topline results confirmed the study's success:

- **Primary Endpoint (Overall Survival):** The study met its primary objective. Patients treated with TTFields + Chemotherapy showed a median Overall Survival (mOS) of **16.20 months**, compared to **14.16 months** in the control arm with chemotherapy alone. The absolute improvement of **2.04 months** is statistically significant (HR=0.819; P=0.039).⁴
- **Analysis of Clinical Significance:** While a two-month gain might appear incremental, in the context of pancreatic cancer, it is transformative. As highlighted by Dr. Vincent Picozzi, principal investigator, this is the first Phase 3 study to demonstrate a survival benefit in this specific patient population.⁴ Furthermore, the survival curves show separation that increases over time, with a **13%** improvement in 12-month survival and **33%** at 24 months.⁴ This suggests that for patients who can tolerate and maintain therapy, the long-term benefit ("tail effect") is substantial.

4.2 Quality of Life and Pain-Free Survival

An often underestimated but commercially powerful aspect of PANOVA-3 is the impact on quality of life. Pancreatic cancer is extremely painful due to infiltration of the celiac nerve plexuses.

The study demonstrated a statistically significant extension of Pain-Free Survival (survival free from severe pain) of a remarkable 6.1 months (15.2 months in the TTFields arm vs 9.1 months in control; HR 0.74).²²

This data point is crucial for adoption: it offers oncologists a compelling argument to propose a device-based therapy ("not only will you live longer, but you will live with less pain for longer").

4.3 Pancreas Regulatory Catalysts 2026

The roadmap for commercialization in pancreas is clear and packed with events in 2026:

- **Full Data Presentation:** Full data will be presented in an oral session at ASCO 2025 or ASCO GI, providing the granular details needed to convince the scientific community.²⁴
- **FDA Decision (PMA):** NovoCure plans to submit the Premarket Approval (PMA) application in the second half of 2025. Based on standard FDA review timelines, the final decision is expected in the **second half of 2026** (likely Q3 or Q4).²⁵
- **Market Potential:** Approval would open a market of approximately 40,000 annual patients (US+EU5) who currently have no options after chemotherapy. Given the lack of approved competition in this specific setting (beyond chemo), adoption could be faster compared to lung.

4.4 PANOVA-4: Expansion to Metastatic

While PANOVA-3 covers locally advanced disease, the Phase 2 PANOVA-4 study explores the

use of TTFIELDS in the metastatic setting (which represents the majority of cases) in combination with immunotherapy (atezolizumab) and chemotherapy.

Topline data from this study are expected in Q1 2026.²⁵

- **Strategic Implication:** A positive result in PANOVA-4 would validate the hypothesis that TTFIELDS can synergize with checkpoint inhibitors even in "cold" gastrointestinal tumors, paving the way for a future Phase 3 study in metastatic disease and exponentially expanding the Total Addressable Market (TAM).

5. The Lung Cancer Franchise (NSCLC): Challenges and Potential

Entry into the non-small cell lung cancer (NSCLC) market represents NovoCure's largest volume opportunity, but also its most complex commercial challenge. The FDA approval of **Optune Lua** in October 2024 for the treatment of metastatic NSCLC post-platinum marked the beginning of this era.²⁸

5.1 Analysis of the LUNAR Study and Positioning

The approval is based on data from the LUNAR study, which showed a significant improvement in Overall Survival (OS) when TTFIELDS were added to standard of care (docetaxel or immune checkpoint inhibitors). The benefit was particularly marked in the subgroup treated with immunotherapy (median OS 18.5 months vs 10.8 months).¹⁵ However, commercial adoption in 2025 was slow, with only 100 active patients as of September 30, 2025.⁷

The reasons for this slowness are manifold:

1. **Logistical Complexity:** Unlike neuro-oncologists, thoracic oncologists do not have prior familiarity with prescribing a wearable device. The sales cycle requires education not only of the physician but of the entire nursing staff.
2. **Pharmacological Competition:** The second-line NSCLC market is crowded. New classes of drugs, such as Antibody-Drug Conjugates (ADCs) (e.g., Datopotamab deruxtecan), are entering guidelines, competing for prescriber "share of mind."³⁰
3. **NCCN Guidelines:** Updating NCCN guidelines is a critical step. Currently, positioning as Category 1 or 2A is essential to guarantee automatic reimbursement by US private insurers. The company awaits updates consolidating this recommendation during 2026.⁸

5.2 METIS: The Keystone for Adoption

If LUNAR opened the door, the **METIS** study could be the key to throwing it wide open. This Phase 3 study evaluated TTFIELDS in the treatment of brain metastases from NSCLC following stereotactic radiosurgery (SRS).

- **Results:** The study met its primary endpoint, significantly delaying time to intracranial progression (i.e., the appearance of new metastases in the brain).³

- **Strategic Value:** METIS is fundamental because it targets neuro-oncologists, NovoCure's loyal customer base. A neuro-oncologist treating brain metastases in a lung patient will prescribe Optune. This creates an entry point for the device in the lung patient's care journey, bypassing the initial resistance of the thoracic oncologist.
- **Catalyst:** The FDA decision on the PMA submission based on METIS is expected in **Q4 2026**.²⁵ Approval would create immediate commercial synergy between the GBM and Lung franchises.

5.3 LUNAR-2: The Future of First Line

Looking beyond 2026, the **LUNAR-2** study represents the true "Blue Sky scenario." This study is testing TFields in first-line metastatic disease in combination with Pembrolizumab and platinum-based Chemotherapy. Enrollment is ongoing and represents the attempt to insert Optune into the global standard of care for the majority of patients diagnosed with advanced NSCLC.¹⁵

6. The Glioblastoma Franchise (GBM): Defense and Renewal

Despite expansion, GBM remains the company's primary source of cash. The strategy here is twofold: defend market share in mature countries (USA, Germany) and expand it through new clinical evidence allowing for earlier therapy initiation.

6.1 Performance and Current Market

In Q3 2025, the GBM segment showed surprising vitality for a mature product. Active patients reached a record 4,277, up 5% YoY. Growth is driven by international markets (+27% in France, +8% in Japan), offsetting saturation in the US market.⁷

This demonstrates that, despite the perception of "old technology," Optune remains an irreplaceable standard of care in GBM, lacking true approved direct competitors offering comparable survival benefits.

6.2 The TRIDENT Study: The Most Important Catalyst of 2026

The Phase 3 **TRIDENT** (EF-32) study is undoubtedly the most important clinical event of 2026 for NovoCure.


- **Study Design:** TRIDENT tests the use of Optune Gio starting *concomitantly* with radiotherapy (RT) and temozolomide (TMZ) in newly diagnosed patients. Currently, the standard involves starting Optune only *after* the end of radiotherapy (adjuvant phase).
- **Scientific Rationale:** As discussed in the scientific section, TFields inhibit DNA repair. Using them during radiotherapy should sensitize tumor cells to radiation damage, increasing cytotoxic efficacy (radiosensitizing synergy).¹⁴
- **Commercial Impact:** If the data expected in **Q2 2026** are positive ²⁵, they will change the global standard of care. Optune would become an integral part of initial intensive

therapy for *all* GBM patients. This would not only increase therapy duration (starting months earlier) but drastically increase the penetration rate, which in the US is stuck around 40%. A success in TRIDENT could increase the value of the GBM franchise by 30-50%.

Mappa delle Opportunità di Mercato: Attuale vs. Futuro

Posizionamento Strategico Indicazioni

● Dimensione Bolla = Potenziale Ricavi



Analisi del portafoglio indicazioni. Mentre il GBM (in alto a destra) è un mercato maturo ma di nicchia, il NSCLC e il Pancreas (al centro e sinistra) rappresentano mercati molto più vasti in fase di sblocco normativo.

Data sources: [Motley Fool \(Transcript Q3 2025\)](#), [Public.com \(Analyst Ratings\)](#), [Stockhouse \(Catalysts 2026\)](#)

7. Risk Analysis and Mitigation Factors

Investing in NovoCure in 2026 is not without risks. The binary nature of clinical events and the complexities of market access require careful evaluation.

7.1 Reimbursement and Market Access Risk

The main risk is no longer regulatory approval, but reimbursement.

- **Germany Scenario:** In Germany, the largest EU market, the NSCLC launch was slowed by the lack of an upfront reimbursement agreement. NovoCure must negotiate

case-by-case or provide the device for free ("compassionate use") to penetrate the market, which hurts margins and slows revenue growth.⁷

- **Mitigation:** Inclusion in national and international clinical guidelines (e.g., ESMO, NCCN) is the key factor to unlock payers. Approval in Japan, a country with a centralized and efficient reimbursement system, offers a positive counterweight.⁵

7.2 Competition and Patient Compliance

- **Compliance:** The therapy requires the patient to wear the device for at least 18 hours a day. In metastatic NSCLC, where patients are often symptomatic and frail, compliance might be lower than in GBM, reducing clinical efficacy and adoption.
- **Competition:** In pancreas, the landscape is less crowded, making PANOVA-3 a unique opportunity. In lung, however, competition is fierce. Yet, the "add-on" nature of TTFields (added to therapy, not replacing it) mitigates the risk of direct substitution.

8. Conclusions and Outlook

NovoCure presents itself in 2026 as a company deeply undervalued relative to the intrinsic potential of its technology platform. The current market is pricing the company almost exclusively based on the existing GBM business, attributing very low "option-like" value to the nascent Lung and Pancreas franchises due to uncertainty over commercial adoption timing.

However, the fundamentals tell a different story:

1. **Financial Stability:** With **\$448 million in cash**, no imminent convertible debt, and a clear path to operational break-even, downside financial risk has been drastically reduced.
2. **Clinical Validation:** Successes in PANOVA-3 and METIS have demonstrated that the technology works outside the brain.
3. **Rich Catalysts:** 2026 offers four major events (PANOVA-4 Data, TRIDENT Data, Pancreas FDA Decision, METIS FDA Decision) that can act as powerful drivers for re-rating.

In conclusion, for investors willing to tolerate volatility related to reimbursement timing, NovoCure offers an asymmetric risk-reward profile, with the concrete possibility of transforming from a niche leader in the brain to a global oncology platform within the next 24 months.

Bibliografia

1. Novocure Investor Relations | NVCR IR | revenue & financials, accesso eseguito il giorno gennaio 18, 2026, <https://www.novocure.com/investor-relations/investor-relations/home>
2. Novocure (NVCR) Stock Forecast: Analyst Ratings, Predictions & Price Target 2026, accesso eseguito il giorno gennaio 18, 2026, <https://public.com/stocks/nvcr/forecast-price-target>

3. Novocure Press Releases | Latest NVCR News, accesso eseguito il giorno gennaio 18, 2026, <https://www.novocure.com/press-releases>
4. Novocure Announces Positive Topline Results from Phase 3 PANOVA-3 Clinical Trial of Tumor Treating Fields (TTFIELDS) Therapy for Pancreatic Cancer, accesso eseguito il giorno gennaio 18, 2026, <https://www.novocure.com/novocure-announces-positive-topline-results-phase-3-panova-3-clinical-trial-tumor-treating-fields>
5. Optune Lua Secures Japanese Approval for Advanced NSCLC | Onclive, accesso eseguito il giorno gennaio 18, 2026, <https://www.onclive.com/view/optune-lua-secures-japanese-approval-for-advanced-nsclc>
6. Novocure reports \$655 million in preliminary 2025 revenue - Investing.com, accesso eseguito il giorno gennaio 18, 2026, <https://www.investing.com/news/company-news/novocure-reports-655-million-in-preliminary-2025-revenue-93CH-4441521>
7. NovoCure (NVCR) Q3 2025 Earnings Call Transcript | The Motley Fool, accesso eseguito il giorno gennaio 18, 2026, <https://www.fool.com/earnings/call-transcripts/2025/11/27/novocure-nvcr-q3-2025-earnings-call-transcript/>
8. Novocure outlines four-indication expansion and profitability target for 2027 as GBM growth continues - Seeking Alpha, accesso eseguito il giorno gennaio 18, 2026, <https://seekingalpha.com/news/4511676-novocure-outlines-four-indication-expansion-and-profitability-target-for-2027-as-gbm-growth>
9. Novocure Announces Preliminary Full Year and Fourth Quarter 2025 Performance and Provides Company Update - BioSpace, accesso eseguito il giorno gennaio 18, 2026, <https://www.biospace.com/press-releases/novocure-announces-preliminary-full-year-and-fourth-quarter-2025-performance-and-provides-company-update>
10. Novocure pipeline | oncology clinical trials with TTFIELDS, accesso eseguito il giorno gennaio 18, 2026, <https://www.novocure.com/our-pipeline>
11. Recent advances in Tumor Treating Fields (TTFIELDS) therapy for glioblastoma - PMC, accesso eseguito il giorno gennaio 18, 2026, <https://pmc.ncbi.nlm.nih.gov/articles/PMC11883162/>
12. EF-33 - Recurrent Glioblastoma Clinical Trial | Novocure Trials, accesso eseguito il giorno gennaio 18, 2026, <https://www.novocuretrials.com/cancer-clinical-trials/recurrent-glioblastoma-clinical-trial-ef-33>
13. PANOVA-3 - Pancreatic Cancer Clinical Trial, accesso eseguito il giorno gennaio 18, 2026, <https://www.novocuretrials.com/cancer-clinical-trials/pancreatic-cancer-clinical-trial-panova-3>
14. NVCR - NovoCure Limited | News - OTC Markets, accesso eseguito il giorno gennaio 18, 2026, <https://www.otcmartets.com/stock/NVCR/news/Novocure-to-Present-New-Rese>

[arch-for-Tumor-Treating-Fields-TTFields-Therapy-at-European-Association-of-Neuro-Oncology-EA?e&id=3330816](#)

15. LUNAR-2: Pivotal, randomized, open-label study of tumor treating fields (TTFields, 150 kHz) concomitant with pembrolizumab and platinum based chemotherapy for the treatment of metastatic non-small cell lung cancer. - ASCO Publications, accesso eseguito il giorno gennaio 18, 2026, https://ascopubs.org/doi/10.1200/JCO.2024.42.16_suppl.TPS8665
16. NCT04471844 | Pivotal, Randomized, Open-label Study of Optune® (Tumor Treating Fields) Concomitant With RT & TMZ for the Treatment of Newly Diagnosed GBM | ClinicalTrials.gov, accesso eseguito il giorno gennaio 18, 2026, <https://clinicaltrials.gov/study/NCT04471844>
17. Novocure Reports Third Quarter 2025 Financial Results - TradingView, accesso eseguito il giorno gennaio 18, 2026, <https://www.tradingview.com/news/tradingview:d5b74b1077e5e:0-novocure-reports-third-quarter-2025-financial-results/>
18. Novocure Reports Third Quarter 2025 Financial Results - Business Wire, accesso eseguito il giorno gennaio 18, 2026, <https://www.businesswire.com/news/home/20251030825661/en/Novocure-Reports-Third-Quarter-2025-Financial-Results>
19. NovoCure Ltd (NVCR) Q3 2025 Earnings Summary - Fintool, accesso eseguito il giorno gennaio 18, 2026, <https://fintool.com/app/research/companies/NVCR/earnings/Q3%202025>
20. Novocure reports FY25 preliminary net revenues of \$655.4M | Seeking Alpha, accesso eseguito il giorno gennaio 18, 2026, <https://seekingalpha.com/news/4538515-novocure-reports-fy25-preliminary-net-revenues-of-6554m>
21. Zai Lab and Novocure Announce Positive Topline Results from Phase 3 PANOVA-3 Clinical Trial of Tumor Treating Fields (TTFields) Therapy for Pancreatic Cancer, accesso eseguito il giorno gennaio 18, 2026, <https://ir.zailaboratory.com/news-releases/news-release-details/zai-lab-and-novocure-announce-positive-topline-results-phase-3>
22. Zai Lab and Novocure Announce Results From the Phase 3 PANOVA-3 Trial of Tumor Treating Fields (TTFields) Therapy for Pancreatic Cancer to be Presented at 2025 ASCO Annual Meeting - Investor Overview, accesso eseguito il giorno gennaio 18, 2026, <https://zailab.gcs-web.com/news-releases/news-release-details/zai-lab-and-novocure-announce-results-phase-3-panova-3-trial/>
23. Results From the Phase 3 PANOVA-3 Trial of Novocure's Tumor Treating Fields (TTFields) Therapy for Pancreatic Cancer to be Presented at 2025 ASCO Annual Meeting - FirstWord Pharma, accesso eseguito il giorno gennaio 18, 2026, <https://firstwordpharma.com/story/5967758>
24. Novocure Reports Second Quarter 2025 Financial Results - FirstWord Pharma, accesso eseguito il giorno gennaio 18, 2026, <https://firstwordpharma.com/story/5983680>
25. Novocure Announces Preliminary Full Year and Fourth Quarter 2025 Performance

- and Provides Company Update - Stockhouse, accesso eseguito il giorno gennaio 18, 2026,
<https://stockhouse.com/news/press-releases/2026/01/12/novocure-announces-preliminary-full-year-and-fourth-quarter-2025-performance-and>
26. Novocure Files Premarket Approval Application to FDA for Tumor Treating Fields Therapy in Locally Advanced Pancreatic Cancer | OncLive, accesso eseguito il giorno gennaio 18, 2026,
<https://www.onclive.com/view/novocure-files-premarket-approval-application-to-fda-for-tumor-treating-fields-therapy-in-locally-advanced-pancreatic-cancer>
 27. Novocure's Tumor Treating Fields Device Breaks New Ground in Pancreatic Cancer Treatment - Claritas Rx, accesso eseguito il giorno gennaio 18, 2026,
<https://www.claritasrx.com/thought-leadership/novocure-cancer-treatment/>
 28. Tumor Treating Fields Therapy Receives FDA Approval in Metastatic NSCLC, accesso eseguito il giorno gennaio 18, 2026,
<https://ascopost.com/issues/november-10-2024/tumor-treating-fields-therapy-receives-fda-approval-in-metastatic-nsclc/>
 29. Novocure's Optune Lua® Receives Approval in Japan for the Treatment of Unresectable Advanced/Recurrent Non-Small Cell Lung Cancer (NSCLC) - Business Wire, accesso eseguito il giorno gennaio 18, 2026,
<https://www.businesswire.com/news/home/20250915117838/en/Novocures-Optune-Lua-Receives-Approval-in-Japan-for-the-Treatment-of-Unresectable-Advanced-Recurrent-Non-Small-Cell-Lung-Cancer-NSCLC>
 30. NCCN Releases NSCLC Guideline Update, Dato-DXd Designated as a Preferred Second-Line Regimen in EGFR-Mutated Disease | OncLive, accesso eseguito il giorno gennaio 18, 2026,
<https://www.onclive.com/view/nccn-releases-nsclc-guideline-update-dato-dxd-designated-as-a-preferred-second-line-regimen-in-egfr-mutated-disease>
 31. Novocure to Present Final Results from the Pivotal Phase 3 METIS Trial of its Tumor Treating Fields (TTFields) Therapy for Brain Metastases from Non-Small Cell Lung Cancer at 2025 ASTRO Annual Meeting - FirstWord Pharma, accesso eseguito il giorno gennaio 18, 2026, <https://firstwordpharma.com/story/6228369>
 32. EF-32 TRIDENT - NHS Health Research Authority, accesso eseguito il giorno gennaio 18, 2026,
<https://www.hra.nhs.uk/planning-and-improving-research/application-summaries/research-summaries/ef-32-trident/>